27 March 2023 - CHMP opinion for miglustat, the oral enzyme stabiliser component of AT-GAA, on track for 2Q, 2023. ...
21 March 2023 - Milestone marks third Dupixent European Commission approval in the past four months. ...
3 March 2023 - Third authorised indication in Europe for Reblozyl, a first in class treatment for patients with diseases ...
1 March 2023 - Approval is based on Phase 3 ARASENS trial data. ...
24 February 2023 - The positive CHMP opinion is based on Phase 3 data showing treatment with ruxolitinib cream resulted in ...
27 February 2023 - The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance ...
24 February 2023 - Eight new medicines recommended for approval ...
24 February 2023 - Merck and Ridgeback Biotherapeutics today announced that the CHMP of the EMA has recommended the refusal ...
24 February 2023 - Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to ...
24 February 2023 - European Commission decision anticipated in beginning of May 2023. ...
24 February 2023 - The positive CHMP opinion is based on results from the Phase 3 MAGNITUDE study where the ...
23 February 2023 - Akebia Therapeutics today announced that the CHMP of the EMA has adopted a positive opinion recommending ...
22 February 2023 - Approval based on ELEVATE-PLUS trials which showed bioequivalence and consistent dosing versus current capsule. ...
20 February 2023 - Hemgenix underscores CSL's promise to deliver life-changing innovations that have the potential to help patients lead ...
8 February 2023 - UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union for the treatment of ...